Variations in the medical treatment of inflammatory bowel disease among gastroenterologists

Shailendra Singh, Monica Chowdhry, Shifa Umar, Mohammad Bilal, Kofi Clarke

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and aims: With expanding available treatment options and evolving understanding of the risks and benefits of medical therapies for inflammatory bowel disease (IBD), there is the possibility of significant variations in treatment and outcomes. Little is known about the variation in treatment between IBD specialists and other gastroenterology (GI) physicians. Evaluating possible variations is an important first step to help address standardized care and optimize treatment. We studied the differences in use of biologics and immunomodulators in the management of IBD patients at a tertiary care hospital between IBD-trained physicians and other gastroenterologists. Methods: A total of 325 IBD patients were included in the analysis. Of these, 216 patients received care with an IBD physician and 109 had other GI/non-IBD physicians as their main caregivers. Results: The unadjusted use of immunomodulators (35.6% vs 16.5%, p = 0.001), biologics (45.8% vs 22.9%, p =0.001) and dual therapy (biologics and immunomodulator) (14.4% vs 3.7%, p =0.001) was significantly higher in the IBD-physician group. These differences in therapy between the two groups remained after adjusting for patient and disease characteristics. Conclusion: There are significant variations in the treatment of patients with IBD by GI physicians. The use of biologics and immunomodulators is higher in GI physicians with dedicated IBD interest and training.

Original languageEnglish (US)
Pages (from-to)61-64
Number of pages4
JournalGastroenterology Report
Volume6
Issue number1
DOIs
StatePublished - Feb 1 2018

Fingerprint

Inflammatory Bowel Diseases
Physicians
Immunologic Factors
Biological Products
Therapeutics
Gastroenterologists
Biological Therapy
Gastroenterology
Tertiary Healthcare
Tertiary Care Centers
Caregivers
Patient Care

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Singh, Shailendra ; Chowdhry, Monica ; Umar, Shifa ; Bilal, Mohammad ; Clarke, Kofi. / Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. In: Gastroenterology Report. 2018 ; Vol. 6, No. 1. pp. 61-64.
@article{9e6c45f1ac30418aa51593f21a17215c,
title = "Variations in the medical treatment of inflammatory bowel disease among gastroenterologists",
abstract = "Background and aims: With expanding available treatment options and evolving understanding of the risks and benefits of medical therapies for inflammatory bowel disease (IBD), there is the possibility of significant variations in treatment and outcomes. Little is known about the variation in treatment between IBD specialists and other gastroenterology (GI) physicians. Evaluating possible variations is an important first step to help address standardized care and optimize treatment. We studied the differences in use of biologics and immunomodulators in the management of IBD patients at a tertiary care hospital between IBD-trained physicians and other gastroenterologists. Methods: A total of 325 IBD patients were included in the analysis. Of these, 216 patients received care with an IBD physician and 109 had other GI/non-IBD physicians as their main caregivers. Results: The unadjusted use of immunomodulators (35.6{\%} vs 16.5{\%}, p = 0.001), biologics (45.8{\%} vs 22.9{\%}, p =0.001) and dual therapy (biologics and immunomodulator) (14.4{\%} vs 3.7{\%}, p =0.001) was significantly higher in the IBD-physician group. These differences in therapy between the two groups remained after adjusting for patient and disease characteristics. Conclusion: There are significant variations in the treatment of patients with IBD by GI physicians. The use of biologics and immunomodulators is higher in GI physicians with dedicated IBD interest and training.",
author = "Shailendra Singh and Monica Chowdhry and Shifa Umar and Mohammad Bilal and Kofi Clarke",
year = "2018",
month = "2",
day = "1",
doi = "10.1093/gastro/gox005",
language = "English (US)",
volume = "6",
pages = "61--64",
journal = "Gastroenterology Report",
issn = "2052-0034",
publisher = "Oxford University Press",
number = "1",

}

Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. / Singh, Shailendra; Chowdhry, Monica; Umar, Shifa; Bilal, Mohammad; Clarke, Kofi.

In: Gastroenterology Report, Vol. 6, No. 1, 01.02.2018, p. 61-64.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Variations in the medical treatment of inflammatory bowel disease among gastroenterologists

AU - Singh, Shailendra

AU - Chowdhry, Monica

AU - Umar, Shifa

AU - Bilal, Mohammad

AU - Clarke, Kofi

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Background and aims: With expanding available treatment options and evolving understanding of the risks and benefits of medical therapies for inflammatory bowel disease (IBD), there is the possibility of significant variations in treatment and outcomes. Little is known about the variation in treatment between IBD specialists and other gastroenterology (GI) physicians. Evaluating possible variations is an important first step to help address standardized care and optimize treatment. We studied the differences in use of biologics and immunomodulators in the management of IBD patients at a tertiary care hospital between IBD-trained physicians and other gastroenterologists. Methods: A total of 325 IBD patients were included in the analysis. Of these, 216 patients received care with an IBD physician and 109 had other GI/non-IBD physicians as their main caregivers. Results: The unadjusted use of immunomodulators (35.6% vs 16.5%, p = 0.001), biologics (45.8% vs 22.9%, p =0.001) and dual therapy (biologics and immunomodulator) (14.4% vs 3.7%, p =0.001) was significantly higher in the IBD-physician group. These differences in therapy between the two groups remained after adjusting for patient and disease characteristics. Conclusion: There are significant variations in the treatment of patients with IBD by GI physicians. The use of biologics and immunomodulators is higher in GI physicians with dedicated IBD interest and training.

AB - Background and aims: With expanding available treatment options and evolving understanding of the risks and benefits of medical therapies for inflammatory bowel disease (IBD), there is the possibility of significant variations in treatment and outcomes. Little is known about the variation in treatment between IBD specialists and other gastroenterology (GI) physicians. Evaluating possible variations is an important first step to help address standardized care and optimize treatment. We studied the differences in use of biologics and immunomodulators in the management of IBD patients at a tertiary care hospital between IBD-trained physicians and other gastroenterologists. Methods: A total of 325 IBD patients were included in the analysis. Of these, 216 patients received care with an IBD physician and 109 had other GI/non-IBD physicians as their main caregivers. Results: The unadjusted use of immunomodulators (35.6% vs 16.5%, p = 0.001), biologics (45.8% vs 22.9%, p =0.001) and dual therapy (biologics and immunomodulator) (14.4% vs 3.7%, p =0.001) was significantly higher in the IBD-physician group. These differences in therapy between the two groups remained after adjusting for patient and disease characteristics. Conclusion: There are significant variations in the treatment of patients with IBD by GI physicians. The use of biologics and immunomodulators is higher in GI physicians with dedicated IBD interest and training.

UR - http://www.scopus.com/inward/record.url?scp=85047572200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047572200&partnerID=8YFLogxK

U2 - 10.1093/gastro/gox005

DO - 10.1093/gastro/gox005

M3 - Article

VL - 6

SP - 61

EP - 64

JO - Gastroenterology Report

JF - Gastroenterology Report

SN - 2052-0034

IS - 1

ER -